NeonMind Biosciences Inc

At NeonMind Biosciences, we believe in mind over matter. We plan to help people change their lives by changing their minds, through treatment with psychedelics.

Recent News

  • NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

    Vancouver, British Columbia--(Newsfile Corp. - June 14, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FSE: 6UF) ("NeonMind" or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce that Robert Tessarolo, President and Chief Executive Officer, will participate in a virtual presentation at the upcoming H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17, 2021.

    2021-06-14 6:00 AM EDT
  • NeonMind Announces Vitasave Will Carry NeonMind Functional Mushroom Products

    Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FSE: 6UF) ("NeonMind"), is pleased to announce that Vitasave has agreed to carry all four of NeonMind's functional mushroom infused coffees through Vitasave's eCommerce platform. NeonMind Announces Vitasave Will Carry NeonMind Functional Mushroom Products To view

    2021-06-10 6:00 AM EDT
  • NeonMind to Commence Trading on the OTCQB Venture Market

    Vancouver, British Columbia--(Newsfile Corp. - May 28, 2021) -  NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FFE: 6UF) ("NeonMind"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce that its shares will commence trading on the OTCQB® Venture Market (the "OTCQB") on May 28, 2021, under the symbol "NMDBF".

    2021-05-28 8:01 AM EDT
  • NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

    Vancouver, British Columbia--(Newsfile Corp. - May 26, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FSE: 6UF) ("NeonMind"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce the formation of a Medical Clinic Advisory Board to guide the planning and operation of NeonMind branded clinics across Canada. Members of the advisory board will be comprised of experts on provincial and local...

    2021-05-26 6:00 AM EDT
  • NeonMind to Present at the Benzinga Global Small Cap Conference

    Vancouver, British Columbia--(Newsfile Corp. - May 10, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FSE: 6UF) ("NeonMind" or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, today announced that Robert Tessarolo, President and Chief Executive Officer, will participate in a virtual presentation at the Benzinga Global Small Cap Conference taking place from May 13-14, 2021.

    2021-05-10 6:00 AM EDT
  • NeonMind Announces New Specialty Clinics Division to Deliver Innovative Mental Health Services, Appoints New VP, Corporate Development

    Vancouver, British Columbia--(Newsfile Corp. - April 22, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTC PINK: NMDBF) (FFE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce that it is establishing a medical services division for the delivery of evidence-backed innovative treatments for a variety of mental health needs. This will include psychedelic modalities and other newer treatments for mood disorders such as depression.

    2021-04-22 6:00 AM EDT
  • NeonMind Developing Music Playlist for Psychedelic Therapy Sessions

    Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) -  NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (OTC PINK: NMDBF) ("NeonMind"), is pleased to announce the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions. Previous research has established that music for a therapeutic psychedelic session can significantly impact the experience. Figure 1: NeonMi

    2021-04-06 6:00 AM EDT
  • NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference

    Vancouver, British Columbia--(Newsfile Corp. - March 30, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) ("NeonMind"), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He will be speaking on the use of psychedelics in treating obesity and eating disorders.

    2021-03-30 6:00 AM EDT